Pub. Date : 2010 Sep
PMID : 20047843
1 Functional Relationships(s)Download |
Sentence | Compound Name | Protein Name | Organism |
| 1 | In non-small cell lung cancer (NSCLC), the strongest clinical evidence is for taxane resistance with elevated expression or mutation of class III beta-tubulin (and possibly alpha tubulin), platinum resistance and expression of ERCC1 or BCRP, gemcitabine resistance and RRM1 expression, and resistance to several agents and COX-2 expression (although COX-2 inhibitors have had minimal impact on drug efficacy clinically). | taxane | ribonucleotide reductase catalytic subunit M1 | Homo sapiens |